Found 121 clinical trials
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Hematology
-
Currently Recruiting
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
>Objective: To test how safe and effective a combination of ibrutinib, short-course fludarabine, and pembrolizumab is for people with chronic lymphocytic leukemia (CLL), also known as
- 47 views
- 23 Nov, 2020
- 1 location
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
Hematology
-
Currently Recruiting
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
, especially T cells. Survival signals through the B-cell receptor can be reduced with ibrutinib, which is a pill taken daily by mouth. Ibrutinib has been approved by the U.S. Food and Drug
- 69 views
- 15 Apr, 2019
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Hematology
-
Currently Recruiting
Response to the HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
getting ibrutinib or acalabrutinib for it. Design: This study lasts 6 months from the date of first vaccination. Participants may be screened with:
- 54 views
- 09 Apr, 2019
- 1 location
-
Unknown Phase
-
Accepting Seniors
-
Accepting adults
-
Hematology
-
Currently Recruiting
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Naive or Receiving Bruton s-Tyrosine Kinase Inhibitor (BTK-I) Therapy
Background: People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles. Scientists had thought people with chronic lymphocytic leukemia (CLL) should not get the shingles vaccine. Now there is a new shingles …
- 206 views
- 09 Apr, 2019
- 1 location
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish
Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …
- 268 views
- 15 Dec, 2020
- 16 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
Hematology
-
Currently Recruiting
A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab,or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
The purpose of this study is to evaluate the safety and tolerability of INCB050465 when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or
- 72 views
- 14 Dec, 2020
- 21 locations
-
Unknown Phase
-
Accepting pediatric ages
-
Accepting adults
-
Currently Recruiting
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
A Study of INCB039110 in Combination With Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- 180 views
- 23 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.
- 64 views
- 08 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 1 trial
-
Accepting pediatric ages
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
- 47 views
- 27 May, 2020
- 50 locations
-
Phase 1 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Hematology
-
Currently Recruiting
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
The purpose of the study is to investigate whether the combination of venetoclax and ibrutinib (administered up to 840 mg per day) might be useful for the treatment of CLL or SLL that is not
- 51 views
- 13 Jan, 2020
- 1 location